Combining intratumoral OBP-502 administration and anti-PD-1 Ab systemic administration in bilateral subcutaneous tumor models has elicited an abscopal effect by gradually repressing both OBP-502-treated tumors and OBP-502-non-treated tumors by active recruitment of CD8+ T cells (69). Here, PDCD1 is linked to neoplasm.